Medtronic, Inc. (MDT) Results Are Better Than Feared, Commentary Appears Cautious - Stifel
Tweet Send to a Friend
Stifel analyst Rick Wise reiterated a Buy rating and $128.00 price target on Medtronic, Inc. (NYSE: MDT) after F3Q22 results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
